Virginia Commonwealth University

VCU Massey Cancer Center

2013 Archive

Drug combination therapy causes cancer cells to “eat themselves”

Paul Dent lab horizontal

Results from a recent preclinical study led by Paul Dent, Ph.D., have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.

Continue reading →

Steven R. Grossman appointed deputy director of Massey

Grossman for blog

Steven R. Grossman, M.D., Ph.D., has been appointed the deputy director of Virginia Commonwealth University Massey Cancer Center. This new position was added to support the continuation of Massey’s upward trajectory and considerable growth over the last few years. As deputy director, Grossman will lead the planning and development of disease-specific scientific research groups; oversee clinical oncology interactions; and develop strategic initiatives in new multidisciplinary research areas.

Continue reading →

An eye on prevention

Alex Krist for blog

Cancer screening can improve the length and quality of life, but the average American receives only half of recommended cancer preventive services. Massey researchers will conduct a new study supported by a multi-year, multi-phase grant from the National Institutes of Health (NIH) to measure whether making personal health records with higher functionality available to primary care physicians and patients promotes shared health decision-making and increases the delivery of cancer screening.

Continue reading →

Massey first in Richmond to offer cutting-edge therapy for metastatic prostate cancer

Radium-223 prostate video

VCU Massey Cancer Center is the first cancer care provider in the Richmond metropolitan region to offer radium-223, an innovative, new drug that has been shown to increase survival and quality of life in patients with metastatic castration-resistant prostate cancer (CRPC). Radium-223 is given intravenously once a month for six months. The treatment is considered to be safe and manageable for both patients and providers and is covered by Medicare.

Continue reading →

Massey’s new neuro-oncologist brings brain cancer expertise to the Richmond area

Malkin for blog

Mark G. Malkin, M.D., F.R.C.P.C., F.A.A.N., joins Virginia Commonwealth University (VCU) Massey Cancer Center as professor of neurology and the Richmond area’s only board-certified neuro-oncologist. Only 1 percent of neurologists in the country specialize in the treatment of neurological cancers, or neuro-oncology, and Malkin joins Asadulah Khan, M.D., assistant professor of pediatrics at Children’s Hospital of Richmond at VCU and Massey, as a fellowship-trained neuro-oncologist.

Continue reading →